Resource Library

Join Dr. Magdalena Richter, Associate Principal Scientist at AstraZeneca, as she details how her team systematically addressed this bottleneck. By benchmarking Nuclera’s eProtein Discovery™ system against standard E. coli cell-based expression, her team asked a critical question: Can a 24-hour, cell-free screen accurately predict expression success at scale?

AI models are generating thousands of promising antibody variants faster than ever before. But because downstream mammalian expression and SPR validation are high-cost and time-consuming, teams are forced into a costly bottleneck—often over-investing in candidates that simply do not bind. Join Sumit Kalsi, Associate Director of Product Research at Nuclera, for insights into the exclusive…

The missing triage step for AI antibody discovery. Download our flyer to discover how Nuclera filters out non-binders before high-cost downstream validation. Learn how our 96-plex full-length IgG binary cell-free expression and binding screen is combined with focused SPR to help you confidently eliminate bad candidates early. Shrink your list without adding CapEx or headcount,…

An overview of eProtein Discovery™ a rapid protein access system located on your benchtop, which enables you to go from DNA to protein in less than 48 hours.

Stop wasting weeks on empirical GPCR detergent screening. This application note demonstrates a rapid, automated cell-free workflow that inserts the β1-adrenergic receptor (β1AR) directly into defined nanodiscs. Using eProtein Discovery™ multiplex screening, researchers can pinpoint optimal lipid environments in 24 hours, scale up to ~100 µg/mL yields, and isolate highly pure, structure-ready GPCRs in less…

This talk delves into recent innovations Bayer Crops have adapted using Nuclera’s eProtein Discovery™ system that is transforming the landscape of membrane protein purification. Dr. Wenguang Liang will discuss high-throughput screening methods that expedite optimization processes, followed by advanced expression systems and novel extraction techniques that enhance both yield and stability.

Join Dr. Tobias Ost, SVP of Product Development at Nuclera, as we unveil our new, expertly curated eProtein Discovery™ GPCR Nanodiscs. Discover how combining cell-free protein synthesis with co-translational insertion directly into pre-assembled nanodiscs stabilizes GPCRs as they are synthesized. Dr. Ost will demonstrate how the eProtein Discovery™ system automates multiplex screening of GPCR constructs…

Fast-track your route to purified, functional GPCRs with our pre-assembled, quality-controlled nanodisc panel. Designed specifically to target the charge, fluidity, and cholesterol needs for GPCR activity, these validated nanodiscs plug seamlessly into the eProtein Discovery™ multiplex screening and scale-up workflow. See how this tunable design space consistently outperforms generic nanodiscs, ensuring you get high yields…

Join Dr. Judith Ronau, Senior Scientist at AbbVie, as she details how her team utilizes cell-free protein expression to eliminate the bottlenecks of traditional cell-based production.

Overcome the traditional bottleneck of obtaining stable, functional GPCRs. This poster demonstrates a rapid workflow that bypasses harsh, slow detergent methods by using cell-free protein synthesis (CFPS) to express the β1-adrenergic receptor (β1AR) directly into defined nanodiscs. Using the eProtein Discovery™ system to automate multiplex screening, researchers can identify the optimal lipid environment to deliver…